Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After=2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study

被引：0

作者：

Schuster, Stephen J. ^{[1
]}

Sehn, Laurie H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Matasar, Matthew ^{[4
]}

Assouline, Sarit ^{[5
]}

Giri, Pratyush ^{[6
]}

Kuruvilla, John ^{[7
]}

Shadman, Mazyar ^{[8
,9
]}

Cheah, Chan Y. ^{[10
,11
]}

Dietrich, Sascha ^{[12
]}

Fay, Keith ^{[13
,14
]}

Ku, Matthew ^{[15
]}

Nastoupil, Loretta ^{[16
]}

Wei, Michael C. ^{[17
]}

Yin, Shen ^{[17
]}

To, Iris ^{[17
]}

Huang, Jiangeng ^{[17
]}

Kwan, Antonia ^{[17
]}

Penuel, Elicia ^{[17
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[2] Univ British Columbia, BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[4] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[5] Jewish Gen Hosp, Montreal, PQ, Canada

[6] Royal Adelaide Hosp, Adelaide, Australia

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[9] Univ Washington, Seattle, WA USA

[10] Sir Charles Gairdner Hosp, Linear Clin Res, Nedlands, Australia

[11] Univ Western Australia, Perth, Australia

[12] Heidelberg Univ, Heidelberg, Germany

[13] St Vincents Hosp, Sydney, Australia

[14] Royal North Shore Hosp, Sydney, Australia

[15] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Genentech Inc, South San Francisco, CA USA

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

IBCL; non-Hodgkin lymphoma; indolent lymphoma; follicular lymphoma; bispecific antibody;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-335

引用

页码：S497 / S497

页数：1

共 50 条

[21] Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study
Izutsu, Koji
Ando, Kiyoshi
Nishikori, Momoko
Shibayama, Hirohiko
Goto, Hideki
Kuroda, Junya
Kato, Koji
Imaizumi, Yoshitaka
Nosaka, Kisato
Sakai, Rika
Abe, Maho
Hojo, Seiichiro
Nakanishi, Tadashi
Rai, Shinya
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (05) : 621 - 630
[22] Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
Falchi, Lorenzo
Carlo-Stella, Carmelo
Morschhauser, Franck
Hutchings, Martin
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Mulvihill, Estafania
Lundberg, Linda
Relf, James
Xie, Yuying
Bottos, Alessia
Humphrey, Kathryn
Dickinson, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study
Zinzani, Pier Luigi
Melnichenko, Vladimir
Bouabdallah, Krimo
Walewski, Jan
Majlis, Alejandro
Fogliatto, Laura
Caballero, Dolores
Christian, Beth A.
Gulbas, Zafer
Ozcan, Muhit
Salles, Gilles
Shipp, Margaret A.
Thompson, Seth
Orlowski, Robert J.
Marinello, Patricia
Armand, Philippe
BLOOD, 2020, 136
[24] Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Mehta, Amitkumar
Popplewell, Leslie
Collins, Graham P.
Smith, Sonali M.
Flinn, Ian W.
Bartlett, Nancy L.
Ghosh, Nilanjan
Hacohen-Kleiman, Gal
Huo, Yanan
Su-Feher, Linda
Renard, Camille
Advani, Ranjana
Roschewski, Mark
BLOOD ADVANCES, 2024, 8 (22) : 5855 - 5863
[25] Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.
Friedberg, Jonathan W.
Younes, Anas
Fisher, David C.
Gordon, Leo I.
Moore, Joseph O.
Czuczman, Myron S.
Miller, Thomas P.
Stiff, Patrick J.
Cheson, Bruce D.
Forero-Torres, Andres
McKinney, Byron
Leonard, John P.
BLOOD, 2008, 112 (11) : 369 - 370
[26] ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Mishima, Kazuhiko
Narita, Yoshitaka
Nagane, Motoo
Terui, Yasuhito
Arakawa, Yoshiki
Yonezawa, Hajime
Asai, Katsunori
Fukuhara, Noriko
Sugiyama, Kazuhiko
Shinojima, Naoki
Aoi, Arata
Nishikawa, Ryo
NEURO-ONCOLOGY, 2020, 22 : 57 - 58
[27] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Furman, Richard R.
Wierda, William G.
Schuh, Anna
Devereux, Stephen
Chaves, Jorge M.
Brown, Jennifer R.
Hillmen, Peter
Martin, Peter
Awan, Farrukh T.
Stephens, Deborah M.
Ghia, Paolo
Barrientos, Jacqueline C.
Pagel, John M.
Woyach, Jennifer
Burke, Kathleen
Covey, Todd
Gulrajani, Michael
Hamdy, Ahmed
Izumi, Raquel
Frigault, Melanie M.
Patel, Priti
Rothbaum, Wayne
Wang, Min Hui
O'Brien, Susan M.
Byrd, John C.
BLOOD, 2019, 134
[28] 2-Year Follow-Up Results From the Phase 1-2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 10 - 11
[29] Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Hutchings, Martin
Carlo-Stella, Carmelo
Morschhauser, Franck
Falchi, Lorenzo
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Baumlin, Pauline
Mulvihill, Estefania
Relf, James
Xie, Yuying
Kaufman, Derrick
Lundberg, Linda
Dickinson, Michael
BLOOD, 2023, 142
[30] Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
Asai, Katsunori
Narita, Yoshitaka
Nagane, Motoo
Mishima, Kazuhiko
Terui, Yasuhito
Arakawa, Yoshiki
Yonezawa, Hajime
Fukuhara, Noriko
Sugiyama, Kazuhiko
Shinojima, Naoki
Aoi, Arata
Nishikawa, Ryo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →